PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15124927-6	2004	Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle.	olmesartan	175-185	interleukin 1 beta	Rattus norvegicus	70-78	
15879491-6	2005	Numbers of myocardial interleukin-1beta (IL-1beta)-positive-staining cells (obtained by immunohistochemistry) and quantities of IL-1beta expression (obtained by Western blotting) were significantly lower in rats with EAM given olmesartan treatment compared with rats given vehicle.	olmesartan	227-237	interleukin 1 beta	Rattus norvegicus	22-39	
21383952-6	2011	Treatment with olmesartan attenuated the myocardial mRNA expressions of proinflammatory cytokines, [Interleukin (IL)-1beta, monocyte chemoattractant protein-1, tumor necrosis factor-alpha and interferon-gamma)] and the protein expression of tumor necrosis factor-alpha compared with that of vehicle-treated rats.	olmesartan	15-25	interleukin 1 beta	Rattus norvegicus	100-122	
25947920-11	2015	The IL-1beta and TNF-alpha levels were decreased in the MTX+OLME 5.0 mg/kg (p<0.01 and p<0.05, respectively) compared with the MTX-alone group.	olmesartan	60-64	interleukin 1 beta	Rattus norvegicus	4-12	
23775504-0	2013	Olmesartan decreases IL-1beta and TNF-alpha levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.	olmesartan	0-10	interleukin 1 beta	Rattus norvegicus	21-29	
23775504-6	2013	In addition, the group that was treated with 6 mg/kg olmesartan showed a decreased level of IL-1beta (p < 0.05), and all doses of olmesartan resulted in decreased levels of TNF-alpha.	olmesartan	53-63	interleukin 1 beta	Rattus norvegicus	92-100